Study S000066

Multicentre Phase IV Single Arm Clinical Trial to Evaluate the Safety and Efficacy of a Fixed Ratio Combination of Insulin Glargine and Lixisenatide in Adult Patients With Type 2 Diabetes Who Are Sub Optimally Controlled on Oral Anti-hyperglycemic Drugs and/or Basal Insulin/GLP-1 RA

ClinicalTrials.gov record

Registration

Registration: NCT06716424
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 105
Start: 2025-01-06
Primary completion: 2026-06-12
Lead sponsor: Sanofi
Conditions: Type 2 Diabetes
Interventions: DRUG:iGlarLixi (insulin glargine/lixisenatide)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:U1111-1303-3494

Registered primary outcomes

Percentage of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs) [From Day 1 to Week 25]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.